The Nijmegen-Leiden-Amsterdam 2-tiered Care Path Study

CompletedOBSERVATIONAL
Enrollment

655

Participants

Timeline

Start Date

October 1, 2022

Primary Completion Date

June 30, 2024

Study Completion Date

October 15, 2024

Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
DIAGNOSTIC_TEST

FIB4-score

A score which estimates the risk for advanced liver fibrosis, based on: age, ALT, AST and thrombocytes

DIAGNOSTIC_TEST

Vibration controlled transient elastography

VCTE measures the speed of a mechanically generated shear wave across the liver to derive a liver stiffness measurement (LSM), a marker of hepatic fibrosis

DIAGNOSTIC_TEST

Enhanced Liver Fibrosis test

The ELF-test is a non-invasive blood test that measures three direct markers of liver fibrosis: hyaluronic acid (HA), procollagen III amino-terminal peptide (PIIINP), and tissue inhibitor of matrix metalloproteinase 1 (TIMP-1).

Trial Locations (3)

6525 GA

Radboudumc, Nijmegen

1105AZ

Amsterdam UMC, location AMC, Amsterdam

2333 ZA

Leiden universitair medisch centrum, Leiden

All Listed Sponsors
collaborator

Maag Lever Darm Stichting

OTHER

collaborator

Radboud University Medical Center

OTHER

collaborator

Leiden University Medical Center

OTHER

lead

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER